Pharmacy · Independent exam preparation
California Practice Standards and Jurisprudence Examination for Pharmacists: Free Preparation Guide Study Guide
Practise prescription validation, therapeutic monitoring, patient counseling, and California pharmacy operations through 60 focused concepts and 20 reasoned CPJE drills.
By CertMedbry · Updated 30 October 2026
Learn to identify unsafe prescriptions, interpret monitoring results, explain medication use, and resolve pharmacy compliance problems across all three CPJE domains. These 60 concepts are selective. The Board's complete Detailed Content Outline defines the full examination scope, including additional tasks in compounding, immunization, pharmacist-provided therapies, and pharmacy management. The task crosswalk identifies selected instruction and areas requiring additional study; coverage of a domain does not establish mastery of every task within it.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and licensure pathway does this guide address?
This guide addresses the California Practice Standards and Jurisprudence Examination for Pharmacists, or CPJE, developed by the California State Board of Pharmacy and administered by PSI. It is a pharmacist licensure examination. The Board-linked bulletin identifies CPJE and NAPLEX as separate examinations required for California pharmacist licensure. CPJE is also distinct from NABP's MPJE.
Pharmacist Examination and Licensure Information · CPJE Candidate Information Bulletin — Updated December 2024
How many questions are scored, and which item styles are verified?
The bulletin describes 90 multiple-choice questions, each with four answer options and one correct answer. Seventy-five questions are scored; 15 are unscored pretest questions distributed throughout the examination without identification. These practice materials use independently authored four-option, single-best-answer questions.
How much examination time is available?
Candidates have two hours to complete the examination. The computer tutorial allows up to 15 additional minutes that do not count toward examination time. Restroom breaks do not add examination time. Dividing two hours by 90 questions gives an average of approximately 80 seconds per question for pacing practice.
How is the examination delivered, and can answers be reviewed?
The CPJE is administered by computer at designated PSI test centers. One question appears at a time. After answering and advancing, candidates cannot return to a question or change an earlier answer. The bulletin does not describe adaptive testing. Answer every question: the bulletin states that there is no penalty for guessing.
Which blueprint applies, and how is its coverage allocated?
As of October 29, 2026, the Board's applicant page links the Detailed Content Outline effective June 1, 2022. The Board-linked bulletin is marked Updated December 2024 and reproduces that outline. Its scored-item counts are 23 for Patient Information and Prescription Evaluation, 27 for Clinical Practice, and 25 for Pharmacy Operations. These correspond to calculated shares of 30.67%, 36%, and 33.33%. This guide uses 18, 22, and 20 concepts; questions and flashcards each use 6, 7, and 7.
Pharmacist Examination and Licensure Information · California Board of Pharmacy Detailed Content Outline — Effective June 1, 2022 · CPJE Candidate Information Bulletin — Updated December 2024
Does the outline's effective date determine which laws or clinical recommendations apply?
The outline establishes examination tasks and their allocation. Its 2022 effective date does not freeze pharmacy practice at 2022 requirements. Study applicable current laws, regulations, Board guidance, and clinical authorities alongside the outline. Distinguish enacted statutory changes from regulations still undergoing rulemaking, and use current product labeling for clinical examples.
California Board of Pharmacy Detailed Content Outline — Effective June 1, 2022 · new_laws.pdf · Pending Regulations - California State Board of Pharmacy
How should candidates interpret passing standards and practice-test results?
The bulletin describes a criterion-referenced minimum-competence standard and equating to account for differences among examination versions. A practice percentage should not be converted into a claimed official passing threshold. These 20 questions identify reasoning gaps and support review; they do not predict passing. Review the correct answer by its option text and use the explanation to assess the reasoning behind each choice.
Which examination-day arrangements require advance attention?
The bulletin directs candidates to arrive at least 30 minutes early and present two accepted, unexpired forms of identification, including one with a photograph. Names must match Board and PSI records as specified, including middle-name versus middle-initial differences. Accommodation requests require advance Board approval. Confirm current scheduling, identification, and accommodation instructions before the appointment.
CPJE Candidate Information Bulletin — Updated December 2024 · Pharmacist Examination and Licensure Information
An independent educational guide for California pharmacist licensure candidates. The CPJE assesses California practice standards, clinical application, communication, and jurisprudence. The accompanying questions are original learning drills.
Outline used: Detailed Content Outline effective June 1, 2022, currently linked by the Board as of October 11, 2026; corroborated by the Board-linked PSI Candidate Information Bulletin marked Updated December 2024. The workbook examination label matches the verified official name; the assigned canonical slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Patient Information and Prescription Evaluation: Practice Standards and Jurisprudence23 of 75 scored items (30.67%, calculated)
1.How do you establish a reliable medication history?
A medication history describes what the patient actually uses, including prescription drugs, nonprescription products, supplements, and intermittent medicines. Compare the interview with available dispensing records and clinical documentation because each source can omit relevant information. Record strength, route, schedule, indication, and recent changes when available. A difference between sources is a discrepancy to investigate, rather than proof that either source is automatically correct.
Apply it
A patient's discharge list omits a sleep aid purchased without a prescription. Identify the product and frequency, add it to the working history, and assess its relevance before approving new therapy.
Common pitfall: Copying the electronic list without interviewing the patient can preserve discontinued therapies while missing medicines obtained elsewhere.
AHRQ MATCH Toolkit, Chapter 3: Designing the Medication Reconciliation Process
2.Which details make an allergy history clinically useful?
An allergy entry becomes useful when it identifies the suspected medicine, reaction, timing, severity, and subsequent exposure. These details distinguish an ordinary adverse effect from a reaction that changes future treatment eligibility. Prior ACE inhibitor-associated angioedema has direct implications for lisinopril selection. Record uncertainty explicitly and seek corroborating information; an unexplained allergy label and a documented airway reaction should not be interpreted as equivalent findings.
Apply it
A patient reports a blood-pressure medicine allergy. Further questioning reveals lip and tongue swelling after lisinopril. Document the reaction specifically and resolve a new lisinopril prescription before dispensing.
Common pitfall: Deleting an allergy because the patient cannot explain its mechanism loses safety information. Clarify the observed reaction and preserve unresolved uncertainty.
DailyMed: Lisinopril Tablets · Community Pharmacy/Hospital Outpatient Pharmacy Self-Assessment — Approved January 27, 2026
3.Why does the timing of renal information matter?
Renal assessment requires a result that meaningfully represents the patient's present condition. A previously acceptable value may become misleading after acute illness, dehydration, or hospitalization. Metformin labeling bases renal eligibility on estimated glomerular filtration rate, so an isolated historical serum creatinine does not establish current eligibility. Identify the result, its date, and intervening clinical changes before applying a drug-specific renal criterion to the prescription under review.
Apply it
A patient presents a metformin prescription after hospitalization for acute kidney injury. Obtain the discharge renal assessment and intended treatment plan rather than relying on last year's result.
Common pitfall: Assuming that a familiar chronic dose remains suitable ignores changes in kidney function. Historical tolerance does not establish present eligibility.
4.How do completeness and authenticity checks differ?
Completeness asks whether an order contains the information needed for lawful, accurate dispensing. Authenticity asks whether it genuinely originated from an authorized prescriber. A complete-looking prescription can still be fraudulent, while a genuine order can contain an omission or transcription error. Resolve the specific concern through an appropriate prescriber contact and document the clarification. Administrative acceptance or a successful insurance claim does not independently establish prescription validity.
Apply it
An electronic order contains complete patient details but an unexpected strength and unfamiliar prescriber. Compare available records and verify the order through a reliable contact channel before release.
Common pitfall: Treating a readable prescription as automatically valid confuses legibility with authorization. An unclear entry requires resolution rather than an unsupported assumption.
Community Pharmacy/Hospital Outpatient Pharmacy Self-Assessment — Approved January 27, 2026 · California Board of Pharmacy Detailed Content Outline — Effective June 1, 2022
5.How does indication guide prescription appropriateness?
Appropriateness connects the intended therapeutic goal with the selected drug, dose, route, dosage form, and patient characteristics. A technically complete prescription may still fail that connection. When information conflicts, formulate a focused question identifying the missing indication or intended regimen. This differs from independently inventing an undocumented treatment goal. The outline includes assessment of drug selection, dosage, interactions, dosage form, and delivery system as prescription-evaluation tasks.
Apply it
A patient says a new liquid medicine is intended for oral use, but the order specifies another route. Confirm the intended product and route before product selection and labeling.
Common pitfall: Inferring the route from whichever product is available can convert an unresolved prescribing discrepancy into a dispensing error with an apparently clear label.
California Board of Pharmacy Detailed Content Outline — Effective June 1, 2022 · Community Pharmacy/Hospital Outpatient Pharmacy Self-Assessment — Approved January 27, 2026
6.How do you verify a liquid dose calculation?
Convert the prescribed amount into volume using the actual concentration selected for dispensing: volume equals dose divided by concentration. Keep units visible so milligrams cancel and milliliters remain. Compare the calculated volume with the directions, measuring device, and supply quantity. This confirms internal consistency; it does not prove that the prescribed clinical dose is appropriate. A concentration change requires recalculation even when the milligram dose stays unchanged.
Apply it
An authorized order specifies 150 mg per dose, and the selected liquid contains 50 mg/mL. Calculate 3 mL per dose. Recalculate if another concentration replaces it.
Common pitfall: Reusing old milliliter directions after changing concentration preserves the appearance of continuity while changing the amount of medicine delivered.
Community Pharmacy/Hospital Outpatient Pharmacy Self-Assessment — Approved January 27, 2026 · California Board of Pharmacy Detailed Content Outline — Effective June 1, 2022
7.Which ingredient clues reveal duplicate acetaminophen exposure?
Duplicate exposure occurs when separate products contain the same active ingredient despite different brand names or treatment claims. Acetaminophen appears in pain, cold, and combination prescription products; prescription labels may abbreviate it as APAP or other shortened forms. Review active ingredients and actual use before approving an additional product. The relevant assessment is total acetaminophen exposure across products, rather than whether each individual package seems familiar or appropriately labeled.
Apply it
A patient filling an acetaminophen-containing prescription also buys a nighttime cold product. Review both ingredient lists and intended schedules, explain the duplication, and establish a plan avoiding unintended overlap.
Common pitfall: Different brand names do not establish different ingredients. Checking only prescription medicines misses nonprescription combinations that can substantially increase exposure.
8.Why must nitrate screening include erectile-dysfunction and pulmonary-hypertension medicines?
Nitroglycerin increases cyclic GMP-mediated vasodilation. Phosphodiesterase-5 inhibitors reduce cyclic GMP breakdown, and soluble guanylate cyclase stimulators increase its production. Combining either category with nitroglycerin can produce severe hypotension; sublingual nitroglycerin labeling identifies these combinations as contraindicated. Ask specifically about these medicines because patients may omit intermittent use or prescriptions obtained elsewhere. A normal blood-pressure reading does not remove the interaction or establish that combined use is safe.
Apply it
Before dispensing sublingual nitroglycerin, the pharmacist learns that the patient uses sildenafil intermittently. Clarify recent use and communicate the contraindicated combination so an explicit treatment plan can be established.
Common pitfall: Intermittent use can still create a serious interaction. Do not replace a verified treatment plan with an invented separation interval.
9.When do swallowing and positioning limitations change alendronate eligibility?
Oral alendronate can injure the esophagus if transit is impaired or administration instructions cannot be followed. Tablet labeling contraindicates abnormalities delaying esophageal emptying, such as stricture or achalasia, and inability to sit or stand upright for at least 30 minutes. These eligibility concerns require treatment reassessment. They differ from a patient who can comply but needs clearer instructions about plain water, timing, and remaining upright after the dose.
Apply it
A caregiver reports that a patient prescribed alendronate cannot sit upright because of severe mobility limitations. Resolve the contraindication with the prescriber before dispensing.
Common pitfall: Counseling cannot correct a physical inability to meet administration requirements. Distinguish a knowledge gap from a contraindication before choosing education alone.
10.How do immediate-release and extended-release metformin differ when selecting a product?
Immediate-release and extended-release metformin contain the same active drug but deliver it on different schedules. Immediate-release labeling includes starting at 500 mg twice daily with meals. The cited extended-release product starts at 500 mg once daily with the evening meal and must be swallowed whole without crushing, cutting, or chewing. Equal tablet strengths do not establish matching regimens. Select the authorized release formulation, strength, dose, and schedule together.
Apply it
An order specifies metformin ER 500 mg, two tablets with the evening meal, but the selected stock is immediate release. Replace it with the authorized formulation and verify the completed directions.
Common pitfall: Matching the total daily milligrams does not resolve conflicting formulation and schedule instructions. Establish the intended conversion before changing the regimen.
11.How should requested translated prescription directions and their English version be provided?
Requested translated directions may appear on the prescription container, label, or supplemental document. When translated directions appear on the container or label, English directions must also appear there whenever possible, including outside the patient-centered area. If English cannot fit on the container or label, provide it on a supplemental document. Mandatory translation coverage extends to the languages and directions made available by the Board; additional translations are permitted.
Apply it
Spanish directions fit on the label, but English cannot fit while preserving required information. Supply English on an accompanying document and verify that the patient understands the authorized regimen.
Common pitfall: English need not invariably appear on the container itself. Limited space nevertheless does not justify omitting English or refusing a covered translation request.
Translations of Pill Directions · AHRQ: Use the Teach-Back Method — Tool 5
12.What does a meaningful final dispensing check compare?
The final check compares the authorized prescription with the prepared product, patient identity, container label, quantity, and relevant supporting information. Establish that the item being released matches the intended order and that unresolved discrepancies have been addressed. The Board's self-assessment includes pharmacist verification responsibilities. Repeating a computer-generated description without checking the actual preparation can reproduce an earlier selection or entry error instead of independently detecting it.
Apply it
The label names the ordered strength, but the tablets came from a neighboring stock bottle. Compare the actual tablets and source product with the original order, correct selection, and repeat verification.
Common pitfall: A correct label does not prove that the container holds the correct medicine. Verification must reach the actual dispensed product.
Community Pharmacy/Hospital Outpatient Pharmacy Self-Assessment — Approved January 27, 2026
13.How does the federal Schedule II refill prohibition affect dispensing?
Under the federal rule summarized in the DEA Pharmacist's Manual, Schedule II prescriptions cannot be refilled. A notation authorizing refills does not create lawful refill authority. Additional routine dispensing after full dispensing requires an appropriate legal basis, such as a new prescription. Distinguish refills from separately regulated processes, including partial filling; the refill prohibition alone does not establish every condition governing those other processes.
Apply it
A Schedule II prescription was fully dispensed, but an imported record displays a remaining refill. Correct the misleading entry and obtain a valid new prescription before another routine dispensing.
Common pitfall: A software refill balance is not legal authority. Prescribing, entry, and migration errors can leave an apparent authorization that cannot lawfully be used.
14.Which independent federal limits constrain Schedule III and IV refills?
Federal law permits no more than five refills within six months after a Schedule III or IV prescription's issue date. Prescriber authorization, refill count, and elapsed time must each support the proposed refill. A recent dispensing does not restart the issuance-based period, and a transfer does not create a new prescription. These are federal limits; compliance also requires any applicable California requirements rather than assuming the federal maximum always determines the permitted supply.
Apply it
A prescription issued seven months ago still displays unused refills. Do not process a routine refill against that authorization; obtain a new valid prescription if treatment should continue.
Common pitfall: Unused refills cannot extend the six-month period. Satisfying one independent condition does not compensate for failing another legal requirement.
DEA Pharmacist's Manual — 2022 Edition · Community Pharmacy/Hospital Outpatient Pharmacy Self-Assessment — Approved January 27, 2026
15.Why must preparation records support reconstruction of a compounded product?
Compounding documentation must connect the intended formulation with the materials, calculations, personnel, and preparation actually produced. California's nonsterile compounding provisions require a master formulation record before compounding and a preparation-specific compounding record. Additional record elements include component manufacturers, lot numbers, expiration dates, a unique internal identifier, total quantity, and responsible personnel. These details support verification, investigation, and identification of affected preparations if a component or preparation later presents a quality problem.
Apply it
A liquid's label shows the intended concentration, but the preparation record contains conflicting quantities. Hold release and reconcile the formula, components, and actual preparation before deciding its disposition.
Common pitfall: A plausible final concentration does not resolve conflicting records. Do not substitute remembered assumptions for evidence of what was actually prepared.
16.Which distinctions guide verification of sterile and nonsterile compounded preparations?
Both types require verification of ingredients, quantities, concentration, intended use, and preparation records. Nonsterile preparations follow USP Chapter 795 and California's nonsterile provisions. A compounded stock solution intended as a component of a sterile preparation must meet USP Chapter 797 Category 1, 2, or 3 requirements and California Article 4.6 sterile-compounding provisions; Chapter 795 compliance alone is insufficient. A designated person cannot exceed their license scope, and the PIC must review practices requiring pharmacist judgment when that person is not a pharmacist.
Apply it
A pharmacy documents an oral stock solution under Chapter 795 and proposes using it to prepare an injectable product. Do not release the stock for that sterile use based on its oral-preparation record. Establish compliance with Chapter 797 Category 1, 2, or 3 and Article 4.6 before approving it as a sterile-preparation component; otherwise use a compliant component.
Common pitfall: Correct concentration and a clear-looking solution do not establish sterile suitability. Preparing the final product in a sterile-compounding area does not cure an inadequately prepared stock component.
1735_38_oa.pdf · Frequently Asked Questions - California State Board of Pharmacy
17.How should automated dispensing discrepancies be handled?
Automation depends on correct product loading, accurate electronic mappings, and appropriate verification. A machine can repeatedly select the wrong product if an upstream configuration or replenishment error remains undetected. When the physical product conflicts with the authorized order or system description, stop release and investigate. The outline includes automated drug delivery systems and final checking as separate tasks, so using automation does not eliminate responsibility for establishing dispensing accuracy.
Apply it
An automated unit supplies a strength differing from the order. Isolate the package, check the compartment and mapping, and assess whether other prescriptions could be affected before resuming routine use.
Common pitfall: Overriding a mismatch because the machine usually works can propagate the loading error. Correct the cause as well as the visible prescription.
California Board of Pharmacy Detailed Content Outline — Effective June 1, 2022 · Community Pharmacy/Hospital Outpatient Pharmacy Self-Assessment — Approved January 27, 2026
18.Which checks connect medication administration with an authorized treatment plan?
Before administration, connect the identified patient, intended product, dose, route, timing, and relevant clinical information with a valid order or applicable statutory authority. These checks address medication accuracy and authority to perform the service. California permits pharmacists to administer drugs and biological products ordered by a prescriber and separately authorizes specified pharmacist services. Recognizing a service in the examination outline does not itself establish the patient's eligibility or the practitioner's authority.
Apply it
A patient brings an injection package but no accessible treatment order. Confirm the intended regimen and applicable authorization, and resolve discrepancies between the package, history, dose, and route before administration.
Common pitfall: Possession of medication does not establish an administration order. General professional licensure also does not remove service-specific legal and clinical requirements.
California Board of Pharmacy Detailed Content Outline — Effective June 1, 2022 · new_laws.pdf
Clinical Practice: Practice Standards and Jurisprudence27 of 75 scored items (36%, calculated)
19.How do metformin renal thresholds distinguish initiation from continuation?
Metformin is contraindicated when eGFR is below 30 mL/min/1.73 m², and initiation is not recommended at eGFR 30–45. If a treated patient's eGFR later falls below 45, reassess the benefits and risks of continuing; discontinue if it falls below 30. These are different decisions because labeling distinguishes starting therapy from reassessing established treatment. Apply the actual eGFR and treatment status rather than a broad description such as mild kidney disease.
Apply it
Two patients have eGFR 38. For a first-time user, recommend reconsidering initiation. For an established user, assess the individual benefit-risk balance and monitoring needs rather than assuming automatic continuation.
Common pitfall: A single rule for everyone below 45 erases the initiation-versus-continuation distinction. Prior use never overrides the contraindication below 30.
20.Why are potassium and renal function monitored with lisinopril?
Lisinopril inhibits angiotensin-converting enzyme, reducing angiotensin II and aldosterone effects. Reduced aldosterone activity can increase potassium, while changes in renal hemodynamics can affect kidney function in susceptible patients. Labeling supports monitoring renal function and serum potassium, especially when patient characteristics or interacting therapies increase risk. Blood pressure documents one treatment effect but does not reveal these laboratory complications. Evaluate baseline information, subsequent results, and relevant medication changes together.
Apply it
A patient taking lisinopril begins an unreviewed potassium supplement. Assess the indication, recent potassium and renal results, and added exposure, then coordinate the treatment and monitoring review.
Common pitfall: Controlled blood pressure does not rule out hyperkalemia or worsening kidney function. Include nonprescription supplements when assessing the regimen.
21.When does lisinopril-associated swelling require emergency action?
ACE inhibitor-associated angioedema may involve the lips, tongue, face, glottis, or larynx and can threaten the airway. Tongue swelling or breathing difficulty requires emergency assessment rather than observation at home. Discontinue lisinopril when angioedema occurs, and communicate and document the reaction for subsequent treatment decisions. The decisive cue is potentially dangerous tissue swelling, regardless of whether the medicine was recently started or had previously been tolerated.
Apply it
A patient taking lisinopril for months develops tongue swelling and difficulty breathing. Direct immediate emergency assistance and communicate the suspected reaction so discontinuation and further treatment can be addressed.
Common pitfall: Routine follow-up or advice to take another dose underestimates airway risk. Previous uneventful use does not exclude ACE inhibitor-associated angioedema.
22.How does patient information determine whether a pharmacist service can be offered safely?
California's accepted standard of care considers what a prudent, reasonable pharmacist with similar education, training, experience, resources, and setting would do in a similar situation. Statutory service authority does not eliminate the need for sufficient patient information. A pharmacist may determine that a service cannot be provided safely because information, expertise, or staffing is insufficient, or because providing it would place the patient at risk.
Apply it
A preventive-care request arrives with unresolved medication and allergy information. Identify the information affecting eligibility and obtain it before choosing therapy; assess whether available staffing supports the necessary evaluation and counseling.
Common pitfall: Authority to offer a service is not evidence that every requesting patient qualifies. Conversely, a knowledge gap should be addressed specifically rather than disguised as a blanket legal prohibition.
23.When is OTC omeprazole appropriate, and which findings require referral?
The cited OTC omeprazole 20-mg delayed-release capsule treats frequent heartburn occurring at least two days weekly in adults aged 18 or older. Full effect may take one to four days, so it is unsuitable for immediate relief. Trouble or pain swallowing, vomiting blood, and bloody or black stools exclude self-treatment. Directions specify one capsule before the morning meal daily for 14 days; longer or more frequent courses require medical direction.
Apply it
An adult with recent frequent heartburn and no label exclusions may qualify for the labeled course after medication review. Painful swallowing instead calls for medical assessment.
Common pitfall: Symptom frequency alone does not establish eligibility. Do not extend treatment indefinitely or repeat courses more often than every four months without medical direction.
24.How should alendronate tablets be taken to support absorption and esophageal safety?
Take alendronate tablets after rising with a full glass of plain water, at least 30 minutes before the first food, beverage, or other medication. Remain upright for at least 30 minutes and until after the first food of the day. Food, other beverages, and medicines can interfere with absorption, while water and positioning reduce esophageal exposure. Teach these instructions as an integrated sequence for the tablet product.
Apply it
A patient plans to take weekly alendronate with breakfast coffee and return to bed. Rehearse a revised sequence using plain water, the waiting period, and remaining upright through the first meal.
Common pitfall: Teaching only fasting leaves water and positioning requirements unaddressed. Coffee, juice, and mineral water do not substitute for plain water.
25.How can non-drug management address a specific reflux pattern?
Match lifestyle measures to the patient's symptom pattern. NIDDK advises leaving at least three hours between eating and lying down when reflux occurs at night or while recumbent. Weight loss may help patients who are overweight or have obesity. Identify foods and drinks associated with the individual's symptoms and assess whether reducing them helps. These measures complement treatment; they do not establish that warning symptoms are safe for self-care.
Apply it
A patient with established GERD eats at 10 p.m., lies down at 10:30 p.m., and has nighttime symptoms. Agree on an earlier meal and review the resulting symptom pattern.
Common pitfall: An instruction to eat better supplies no observable behavior to change. Avoid imposing identical food prohibitions without assessing individual triggers.
26.Why should vitamin K intake remain consistent during warfarin therapy?
Warfarin reduces production of vitamin K-dependent clotting factors by interfering with vitamin K recycling. Dietary vitamin K changes can therefore alter anticoagulant response. Counsel about a balanced diet with reasonably consistent vitamin K intake rather than complete avoidance of vegetables. Communicate substantial dietary changes to the anticoagulation team and consider them when interpreting INR results. The useful distinction is consistent intake versus abrupt change, rather than a list of forbidden foods.
Apply it
A patient plans a daily smoothie containing substantial leafy vegetables. Discuss maintaining consistent intake and notify the anticoagulation team so monitoring can account for the dietary change.
Common pitfall: Eliminating every vitamin K-containing food is unnecessarily restrictive and can itself create a major dietary change affecting anticoagulant response.
27.How do smoking intensity and the selected nicotine patch label determine treatment?
Nicotine patches reduce withdrawal symptoms during smoking cessation. The cited product directs adults smoking more than 10 cigarettes daily to use 21 mg daily for four weeks, then 14 mg for two weeks, then 7 mg for two weeks. Those smoking 10 or fewer start with 14 mg for six weeks, then 7 mg for two weeks. Begin on the quit day and combine treatment with behavioral support.
Apply it
An eligible adult smoking eight cigarettes daily selects this product. Plan 14 mg daily for six weeks followed by 7 mg for two weeks, with a quit date and follow-up.
Common pitfall: Schedules differ among products. Do not substitute a memorized duration, cut patches to create doses, or assume every smoker needs the highest strength.
28.Which warfarin counseling cues require urgent evaluation?
Warfarin can cause serious or fatal bleeding. Counseling should identify unusual or persistent bleeding, blood in urine or stool, and concerning symptoms after injury. INR monitoring helps assess anticoagulant effect but does not make new symptoms irrelevant. Significant bleeding requires prompt clinical assessment rather than waiting for the next scheduled laboratory test. Teach routine monitoring responsibilities and the symptom-based action plan in terms the patient can explain.
Apply it
A patient taking warfarin reports black stools and dizziness during a refill call. Direct urgent medical assessment and communicate the bleeding concern instead of merely arranging a routine INR.
Common pitfall: A recent acceptable INR does not exclude current bleeding. Do not use a historical laboratory result to dismiss a new symptom or injury.
29.How do you calculate and assess total adult acetaminophen exposure?
Multiply each product's acetaminophen strength per unit by units per dose and doses taken daily, then add all prescription and nonprescription contributions. FDA's maximum recommended adult total is 4,000 mg daily across products; product directions or individualized recommendations may require less. Liver disease or consumption of three or more alcoholic beverages daily warrants professional review before use. Different package names do not remove duplicate-ingredient risk.
Apply it
Two 325-mg tablets three times daily supply 1,950 mg. A 650-mg cold-product dose twice daily adds 1,300 mg, producing 3,250 mg daily. Review duplication and individual suitability despite the total being below 4,000 mg.
Common pitfall: The daily ceiling is not a diagnostic poisoning threshold. Suspected excessive exposure requires assessment of amount and timing even when symptoms are absent.
30.Why can suspected acetaminophen overdose require action before symptoms appear?
Excess acetaminophen can cause severe liver injury, and the patient may initially have no clear symptoms. FDA advises prompt medical help when too much may have been taken. Determine products, strengths, amounts, and timing while facilitating assessment; do not wait for abdominal pain or jaundice. Recognizing duplicate ingredients helps prevent overdose, but suspected excessive exposure requires a response beyond correcting the future dosing schedule.
Apply it
A patient realizes that several cold and pain products contained acetaminophen and may have exceeded directions yesterday. Facilitate prompt medical or poison-control advice while assembling product and timing information.
Common pitfall: Reassurance based on absent symptoms can delay assessment. Stopping further doses does not evaluate exposure already taken or establish that liver injury will not occur.
31.How does medication reconciliation distinguish discrepancies from intended changes?
Medication reconciliation compares the best available medication history with orders at a transition of care. Differences may represent intentional changes, unintended omissions, duplications, or incorrect details. Determine the intended plan with responsible clinicians and document resolved discrepancies. Combining every available list can create duplicate therapy. The task is to produce one accurate, explained regimen identifying which medicines continue, change, start, or stop, and communicate that plan to the patient.
Apply it
A discharge list contains an older medicine and its apparent replacement. Confirm whether substitution was intended, resolve duplicate entries, and provide a list clearly identifying the final regimen.
Common pitfall: Automatically restarting home medicines assumes every omission is an error. Automatically accepting omissions assumes every change was intentional. Both bypass reconciliation.
AHRQ MATCH Toolkit, Chapter 3: Designing the Medication Reconciliation Process
32.What makes a discharge medication handoff usable?
A useful handoff explains the final regimen and reasons for important changes, including medicines stopped or replaced. Identify unresolved questions and communicate necessary information to the patient and next responsible care team. Reconciliation loses value if the corrected list never reaches people making subsequent decisions. AHRQ's MATCH framework emphasizes a defined process and communication at transitions, rather than treating the medication list as an isolated documentation exercise.
Apply it
The hospital resolves a duplicate medicine, but both prescriptions remain active at the community pharmacy. Communicate the clarified regimen and discontinuation information, then confirm the patient understands the change.
Common pitfall: An unexplained list can leave old prescriptions active and patients uncertain. Completing an internal record does not demonstrate a successful handoff.
AHRQ MATCH Toolkit, Chapter 3: Designing the Medication Reconciliation Process
33.How does teach-back reveal a counseling gap?
Teach-back asks patients to explain the plan in their own words so the clinician can assess how clearly it was communicated. Introduce the request without making it a test of the patient. If the explanation is incorrect, reteach using simpler language or a smaller information segment, then check again. A yes-or-no question cannot demonstrate the patient's interpretation of dose, timing, precautions, or actions when problems occur.
Apply it
After counseling, ask the patient to describe tomorrow's dosing. The patient reverses morning and evening amounts. Re-explain with a simple written aid, then repeat teach-back.
Common pitfall: Asking whether the patient understands invites agreement without demonstrating comprehension. Blaming the patient for an incorrect explanation undermines the purpose of improving communication.
34.When is a return demonstration more informative than verbal recall?
For a device or hands-on medication task, describing steps may not reveal whether the patient can perform them. A return demonstration makes technique observable and allows correction of a specific missed step. Use the supportive approach of teach-back: explain, ask the patient to show the process, reteach the problem area, and reassess. Product instructions define the actual technique; the communication method alone does not establish device-specific requirements.
Apply it
A patient repeats liquid-dose directions correctly but selects the wrong syringe marking. Demonstrate the intended volume and ask the patient to measure it again using the actual home device.
Common pitfall: Verbal repetition can conceal a practical error. Successful performance with one device does not automatically establish competence with a different device.
AHRQ: Use the Teach-Back Method — Tool 5 · California Board of Pharmacy Detailed Content Outline — Effective June 1, 2022
35.How do you distinguish nonadherence from treatment failure?
Apparent lack of response can result from inadequate exposure rather than an ineffective medicine. Ask nonjudgmentally about actual use, understanding, adverse effects, cost, access, and routines before recommending escalation. Compare reported use with prescribing and dispensing information without assuming either proves ingestion. The outline includes resolving nonadherence and assessing understanding. Identify the barrier and match the intervention to its cause instead of reflexively adding treatment.
Apply it
A patient misses most doses because of an unpleasant effect. Communicate actual exposure and the concern so the care team can address tolerability before increasing treatment intensity.
Common pitfall: Refill history can suggest access patterns but does not establish ingestion. Escalation without clarifying use may worsen an unresolved problem or create excessive exposure when adherence improves.
California Board of Pharmacy Detailed Content Outline — Effective June 1, 2022 · AHRQ: Use the Teach-Back Method — Tool 5
36.How should affordability and formulary barriers influence a treatment plan?
A regimen cannot achieve its goal if the patient cannot obtain it. Identify whether the barrier is coverage, cost, availability, or required authorization, then compare feasible options with the clinical goal. A formulary alternative may require a new prescription or authorized interchange process; lower cost does not establish therapeutic equivalence. The outline includes formulary use and affordability resolution, linking access work with clinically appropriate and legally authorized treatment.
Apply it
A patient leaves a new medicine uncollected because of cost. Confirm coverage options and discuss an appropriate covered alternative with the prescriber, then verify authorization and explain any regimen change.
Common pitfall: Choosing the cheapest product without checking suitability and authority can create another treatment problem. Coverage approval alone does not establish clinical appropriateness.
California Board of Pharmacy Detailed Content Outline — Effective June 1, 2022
37.Which findings suggest metformin-associated lactic acidosis?
Metformin-associated lactic acidosis can begin subtly with malaise, myalgias, abdominal pain, respiratory distress, or increasing somnolence. Severe cases can involve hypotension and resistant bradyarrhythmias. Labeling describes elevated lactate above 5 mmol/L and anion-gap acidosis, with increased risk from renal impairment, hypoxic illness, excessive alcohol intake, hepatic impairment, and other factors. Suspected lactic acidosis requires immediate metformin discontinuation and hospital management; prompt hemodialysis is recommended when strongly suspected or diagnosed.
Apply it
A metformin-treated patient with recent acute kidney injury develops respiratory distress and unusual somnolence. Facilitate urgent hospital assessment and communicate the medicine, renal history, and symptoms.
Common pitfall: Do not dismiss systemic deterioration as ordinary gastrointestinal intolerance or wait for routine follow-up. Nonspecific symptoms become more concerning when serious risk factors are present.
38.How do Shingrix eligibility, presentation, and schedule affect administration?
Shingrix labeling indicates prevention of herpes zoster in adults aged at least 50 and adults aged at least 18 who are or will be at increased risk because of immunodeficiency or immunosuppression. Give two 0.5-mL intramuscular doses, ordinarily two to six months apart. Eligible immunocompromised patients benefiting from a shorter schedule may receive the second dose after one to two months. The vial presentation requires reconstitution with its supplied adjuvant; the prefilled syringe does not.
Apply it
Verify the supplied presentation before preparation. After reconstituting the vial presentation, administer immediately or refrigerate at 2–8°C and use within six hours, discarding it if unused by then.
Common pitfall: Shingrix does not prevent primary varicella infection. Prior anaphylaxis to a dose or component contraindicates administration; presentation changes do not remove that contraindication.
39.How does California's standard-of-care model govern pharmacist-furnished preventive medicines?
Changes effective January 1, 2026 authorize pharmacist furnishing of FDA-approved or authorized medicines for specified preventive services not requiring a diagnosis, including contraception, smoking cessation, and travel medication. Practice must meet the accepted standard of care and applicable authority. Under BPC 4052(e), notify the primary care provider or enter information in a shared record as that provider permits. If the patient lacks a primary care provider or requests no notification, give the patient a written or electronic record of furnished drugs or devices and advise consultation with a physician of their choice.
Apply it
An eligible patient requests a pharmacist-furnished preventive medicine and asks that their primary care provider not be notified. After assessing suitability, information, expertise, and staffing, respect that request, provide a written or electronic furnishing record, and advise consultation with a physician of the patient's choice. Several former statutory protocols were repealed, but formal regulatory cleanup remained pending in October 2026.
Common pitfall: Do not treat provider notification as mandatory despite the patient's request for the statutory alternative, or omit the patient record and consultation advice. The standard-of-care transition does not authorize diagnosis and treatment of every condition or make pending regulatory repeals effective.
new_laws.pdf · new_laws.pdf · 26_jan_bd_mat_xii.pdf · Pending Regulations - California State Board of Pharmacy
40.When should metformin be withheld for iodinated contrast imaging?
The cited label directs stopping metformin at or before iodinated contrast procedures when eGFR is 30–60 mL/min/1.73 m², when there is a history of liver disease, alcoholism, or heart failure, or when intra-arterial iodinated contrast will be given. Reassess eGFR 48 hours afterward and restart only if renal function is stable. The concern is contrast-associated renal deterioration increasing metformin accumulation and lactic-acidosis risk.
Apply it
A patient taking metformin has eGFR 52 and is scheduled for iodinated contrast. Coordinate withholding at or before the procedure and arrange the renal reassessment needed to decide on restarting.
Common pitfall: A fixed 48-hour pause does not automatically authorize restarting. Renal stability must be established, and route of contrast administration is an independent qualifying consideration.
Pharmacy Operations: Practice Standards and Jurisprudence25 of 75 scored items (33.33%, calculated)
41.How does receiving verification support inventory traceability?
Receiving verification connects supplier documentation with the products and quantities actually entering inventory. Check mismatches, damage, and information necessary to trace receipt, and resolve discrepancies before making questionable stock available for dispensing. The outline includes sourcing, track and trace, and purchase-receipt records. Familiar product appearance is insufficient when origin or receipt information remains unresolved because later recalls, inventory reconciliation, and investigations depend on reliable records.
Apply it
A shipment contains a strength differing from the invoice and order. Separate affected stock, reconcile documentation and actual receipt, and correct the record before routine dispensing.
Common pitfall: Accepting invoice quantities without inspecting the shipment creates inaccurate inventory immediately. Later discrepancies become harder to distinguish from dispensing errors or unexplained losses.
Community Pharmacy/Hospital Outpatient Pharmacy Self-Assessment — Approved January 27, 2026 · California Board of Pharmacy Detailed Content Outline — Effective June 1, 2022
42.Why must controlled-substance records explain inventory movement?
Controlled-substance records should account for quantities ordered, received, stored, dispensed, returned, and otherwise removed through authorized processes. Connecting these movements supports reconciliation and discrepancy investigation. A final balance does not explain how inventory changed. The outline expressly includes controlled-substance movement records, and the Board's self-assessment addresses accountability. Records must reflect actual transactions rather than unsupported adjustments made solely to force agreement with a desired balance.
Apply it
A physical count differs after a shipment and several dispensings. Review receipts, dispensings, returns, and other movement records to identify the cause before making a supported correction.
Common pitfall: A balanced total can conceal undocumented transactions. Adjusting the number without explaining the underlying movement weakens accountability and future detection.
California Board of Pharmacy Detailed Content Outline — Effective June 1, 2022 · Community Pharmacy/Hospital Outpatient Pharmacy Self-Assessment — Approved January 27, 2026
43.How should a controlled-substance discrepancy be investigated for theft or significant loss?
Recount stock and reconcile receipts, dispensings, returns, adjustments, and access records. Preserve evidence and document findings rather than assuming either a harmless count error or employee theft. Federal significance is circumstance-specific: repeated small losses can form a significant aggregate pattern even when each isolated quantity appears minor. Confirmed theft requires reporting without separately proving a significant quantity. Assess California reporting obligations independently because federal notification does not automatically satisfy state requirements.
Apply it
Repeated shortages occur despite corrected counting procedures. Compare the pattern with dispensing and access records, assess whether it constitutes significant loss, and activate applicable reporting without waiting for every investigative detail.
Common pitfall: There is no universal federal tablet-count threshold. Unsupported accusations and unexplained balance adjustments both undermine a sound investigation.
Federal Register, Volume 88 Issue 119 (Thursday, June 22, 2023) · DEA Diversion Control Division: Theft or Loss Q&A · Community Pharmacy/Hospital Outpatient Pharmacy Self-Assessment — Approved January 27, 2026
44.When must California outpatient dispensing be reported to CURES?
For reportable Schedule II–V dispensings under HSC 11165(d), report no later than one working day after medication is released to the patient. Preparing a prescription awaiting pickup does not start that release-based clock. Effective January 1, 2026, testosterone and mifepristone dispensings must not be reported to DOJ, CURES, or its contracted vendor, including PMP Clearinghouse. Review transmission results so rejected reportable records receive timely correction.
Apply it
A reportable lorazepam prescription prepared Wednesday is released Thursday in a week without holidays. Report by Friday. Exclude a testosterone dispensing released the same day under the specific prohibition.
Common pitfall: The testosterone and mifepristone provision prohibits reporting; it merely does not make reporting optional. Data submission and reviewing a patient's history are separate responsibilities.
Controlled Substance Utilization Review and Evaluation System | State of California - Department of Justice - Office of the Attorney General · ab-82-update-on-reporting-of-testosterone-and-mifepristone.pdf
45.How do initial DEA notification and electronic Form 106 deadlines differ?
For controlled-substance theft or significant loss, notify the local DEA Field Division Office in writing within one business day after discovery. Separately, submit a complete, accurate DEA Form 106 electronically within 45 calendar days after discovery. The final rule effective July 24, 2023 established the electronic submission requirement and 45-day deadline while retaining initial notification. Investigation and documentation must support both obligations rather than postponing notification until all findings are complete.
Apply it
After discovering confirmed theft on Monday, send timely written notification and track the separate 45-calendar-day electronic reporting deadline. Retain supporting reconciliation records and submission evidence.
Common pitfall: Business days and calendar days are different units. Initial written notice does not substitute for Form 106, and confirmed theft has no minimum-quantity exemption.
DEA Diversion Control Division: Theft or Loss Q&A · Federal Register, Volume 88 Issue 119 (Thursday, June 22, 2023)
46.Why is a digital data logger valuable for vaccine storage?
A digital data logger records temperatures over time, revealing excursions that a single current reading can miss. CDC recommends suitable monitoring equipment, including a buffered probe and appropriate calibration documentation. Review recorded information and respond to alarms through a defined process. An acceptable refrigerator display now does not establish that vaccines stayed within their required range overnight, during a power interruption, or throughout an earlier equipment problem.
Apply it
The refrigerator display is normal after a weekend, but the logger documents an overnight excursion. Preserve the time-temperature information and initiate the excursion process before using affected vaccines.
Common pitfall: A normal spot reading cannot erase a prior excursion. Equipment protects inventory only when staff review its information and act appropriately.
47.How should vaccines be handled after a temperature excursion?
An excursion requires prompt measures preventing use while viability is assessed. Label affected vaccines do not use, separate them from usable stock, and maintain appropriate storage. Document temperatures, duration, affected products, and relevant circumstances, then obtain manufacturer or immunization-program guidance. CDC advises against discarding vaccines before obtaining guidance because an excursion alone does not establish that every affected dose is unusable or that any particular dose remains acceptable.
Apply it
An overnight excursion affects several products. Segregate and label them, retain proper storage, and obtain product-specific guidance using the documented exposure before deciding whether to administer or discard.
Common pitfall: Immediate administration and automatic disposal both make unsupported viability decisions. Quarantine preserves stock for assessment while preventing accidental use.
48.What should a vaccine emergency-storage plan make actionable?
An emergency plan identifies responsible personnel, backup storage, transport supplies, temperature monitoring, and steps protecting inventory during equipment or power failure. It must remain usable when the usual coordinator is absent. Advance preparation matters because improvised transport or repeated door opening can create additional exposure. An emergency transfer does not eliminate documentation or the need to assess excursions occurring before, during, or after relocation.
Apply it
A forecast interruption may affect refrigeration overnight. Confirm alternate storage, transport equipment, monitoring, and staff responsibilities in advance, then document movements and temperature history during the response.
Common pitfall: An alternate location is useful only if its storage and transfer arrangements work. Moving vaccines without monitoring can replace one unknown exposure with another.
49.How do lot details determine the response to a drug recall?
Recall notices identify affected products through details such as strength, lot, expiration date, or other identifiers. Compare every specified identifier with stock and available dispensing information to establish affected inventory and patients. Follow the actual instructions for segregation, return, communication, and disposition. A shared brand name does not establish that all inventory is included, while a matching lot number alone may be insufficient when the notice also restricts strength or presentation.
Apply it
A recall covers one strength and lot among several stocked products. Match both identifiers, segregate the affected stock, and use dispensing records and notice instructions to determine required communications.
Common pitfall: Product-name-only matching can remove unaffected inventory or miss the specified presentation. Patient-contact requirements must follow the notice rather than assumptions about every recall.
FDA: Understanding Drug Recalls — What to Know and What to Do
50.Which risks distinguish FDA recall classes?
FDA Class I recalls involve a reasonable probability of serious adverse health consequences or death. Class II involves temporary or medically reversible adverse consequences, or a remote probability of serious consequences. Class III involves products unlikely to cause adverse health consequences. Class describes the health hazard; the notice still determines practical actions. A lower classification does not authorize continued distribution contrary to instructions or justify ignoring a quality problem.
Apply it
A notice identifies a Class II recall with a remote probability of serious harm. Use that classification to understand the hazard while following its specific inventory, return, and communication instructions.
Common pitfall: Recall class cannot replace product identifiers or instructions. Class III does not mean affected products may simply return to routine distribution.
FDA: Understanding Drug Recalls — What to Know and What to Do
51.Why must expired, returned, and quarantined stock remain controlled?
Stock awaiting return, disposal, or quality assessment must remain identifiable and separated from inventory available for dispensing. Document its status and movement so it cannot accidentally re-enter usable stock. Categories can require different authorized handling, particularly for controlled substances. The outline includes disposal and documentation of expired, returned, and recalled products. Removing something from the dispensing shelf begins the process; accountable final disposition completes it.
Apply it
Expired products and an unresolved supplier return occupy an unmarked tote beside usable inventory. Separate categories, document quantities and status, and apply the appropriate return or disposal process.
Common pitfall: Unmarked holding areas can become accidental dispensing sources. Physical separation without status and disposition records also weakens traceability.
Community Pharmacy/Hospital Outpatient Pharmacy Self-Assessment — Approved January 27, 2026 · California Board of Pharmacy Detailed Content Outline — Effective June 1, 2022
52.How does root-cause analysis turn a medication error into a preventive change?
Root-cause analysis reconstructs an error and examines how workflow, information, equipment, labeling, staffing, and verification allowed it to occur or escape detection. Internal quality assurance assesses the cause and appropriate response rather than merely recording that an error happened. The Board's description of existing requirements states that investigation begins as soon as reasonably possible and no later than two business days after discovery. That is a commencement deadline, not a requirement to finish the entire analysis.
Apply it
Two similar containers contributed to a strength error. Document the event and review, identify selection and verification failures, separate the products, strengthen identification controls, and assess whether subsequent errors decline.
Common pitfall: Advice to be more careful does not correct the mechanism. External reporting also does not replace internal investigation, documented findings, and preventive action.
1711_isor.pdf · California State Board of Pharmacy Frequently Asked Questions · California Board of Pharmacy Detailed Content Outline — Effective June 1, 2022
53.Which operational responsibilities accompany California Medication Error Reporting?
CAMER receives required reports through Board-approved ISMP, an ECRI company, for qualifying errors occurring on or after September 1, 2025. Under BPC 4113.1, submit no later than 14 days after discovery and retain compliance records for three years, immediately available to inspectors. Reportable errors include unauthorized variations from prescription orders; variations corrected before dispensing to the patient or agent and variations allowed by law are excluded. An outpatient hospital pharmacy need not duplicate reporting of an error qualifying as an adverse event already reported to CDPH under HSC 1279.1. Nonresident pharmacies licensed under BPC 4112 report only errors involving prescriptions dispensed to California residents.
Apply it
A wrong strength caught and corrected before dispensing is excluded from CAMER reporting. If the wrong strength reaches the patient, assess safety immediately and, absent an applicable exception, report within 14 days of discovery. Collect the medicine, event, process stage, harm, technology, contributing factors, and narrative. Retain compliance records for three years and begin the separate internal QA investigation as soon as reasonably possible, no later than two business days after discovery.
Common pitfall: The external reporting deadline does not postpone internal QA or replace corrective action. An intercepted variation's exclusion from mandatory CAMER reporting does not make it irrelevant to error-prevention work; the hospital exception requires the specified adverse-event report, not merely any internal incident record.
camer_fact_sheet.pdf · new_laws.pdf · Frequently Asked Questions - California State Board of Pharmacy · 1711_isor.pdf
54.Which quality measure can demonstrate that a safety intervention helped?
A useful measure links the intervention with the error mechanism or patient outcome it should change. Define the event, population, time period, and comparison so results are interpretable. Training attendance documents activity; recurrence of the targeted error assesses performance. The outline includes quality measures, medication-use evaluation, and patient outcomes. Also examine whether the intervention creates another problem elsewhere, because improvement in one step does not guarantee improvement across the process.
Apply it
After separating confused strengths, compare verified selection errors over similar dispensing activity before and after the change. Check for new retrieval problems rather than counting attendance as the sole outcome.
Common pitfall: Lower raw error counts may reflect fewer prescriptions. Distinguish completion of an intervention from evidence of benefit using a meaningful denominator or comparison.
California Board of Pharmacy Detailed Content Outline — Effective June 1, 2022 · Community Pharmacy/Hospital Outpatient Pharmacy Self-Assessment — Approved January 27, 2026
55.Which conditions govern assignment of expanded technician duties?
Under Board guidance for January 1, 2026 changes, qualified technicians may prepare and administer influenza and COVID-19 vaccines by injection or intranasally. They must maintain qualifying certification under BPC 4202(a)(4), work under direct pharmacist supervision and control, and have another scheduled pharmacy technician assisting the pharmacist with traditional duties. Before vaccine administration, the technician must successfully complete at least six hours of ACPE-approved practical training covering hands-on injection technique, recognition and treatment of emergency vaccine reactions, and assessment of injection technique, and hold basic life support certification.
Apply it
A technician maintains qualifying certification, has the six-hour practical training and basic life support certification, and works under direct pharmacist supervision. However, only a clerk is available for traditional duties. The influenza-vaccine assignment remains ineligible until another pharmacy technician is scheduled for those duties. Similarly, these vaccine provisions do not authorize technician administration of Shingrix.
Common pitfall: Training, certification, supervision, permitted vaccine type, and concurrent staffing are independent conditions. Expanded technical duties do not confer independent pharmacist-level clinical judgment, and a clerk does not satisfy the additional-technician requirement.
California State Board of Pharmacy Frequently Asked Questions · Frequently Asked Questions - California State Board of Pharmacy
56.Which events trigger a new California pharmacy self-assessment within 30 days?
The January 27, 2026 community and hospital outpatient form requires PIC completion by July 1 of odd-numbered years. A new assessment is also required within 30 days after a new pharmacy license, appointment of a new PIC, or relocation to a new address. Each required assessment uses a newly completed form rather than a copy of the previous assessment. Retain completed assessments at the pharmacy for three years.
Apply it
A new PIC begins September 1, 2026. Complete a new assessment by October 1 despite a recent assessment by the outgoing PIC; the next regular deadline remains July 1, 2027.
Common pitfall: Even-numbered years do not suspend event-triggered duties. A recently completed form does not eliminate an independent new-PIC or relocation trigger.
Community Pharmacy/Hospital Outpatient Pharmacy Self-Assessment — Approved January 27, 2026
57.How does role-based access implement HIPAA's minimum-necessary principle?
HIPAA generally requires reasonable efforts to limit protected health information to what is necessary for the purpose when the minimum-necessary standard applies. For workforce access, identify roles needing information, the categories needed, and appropriate access conditions. Employment does not create unlimited access to every patient record. Policies should connect permissions with actual duties while permitting necessary care, rather than relying on convenience or an assumption that all employees require the same information.
Apply it
A staff role lacking clinical responsibilities requests unrestricted profile access. Identify information needed for its tasks and configure permissions accordingly, documenting any justified broader access.
Common pitfall: The broadest possible access is not justified simply because it simplifies administration. Minimum necessary is contextual and should not obstruct legitimate work.
58.When does HIPAA's minimum-necessary standard have a treatment exception?
HHS explains that minimum necessary does not apply to disclosures to, or requests by, a health care provider for treatment. This permits treatment exchange without applying that particular restriction. It does not eliminate safeguards, identity verification, or other privacy responsibilities. Distinguish a genuine provider treatment request from unrelated disclosure or access: both recipient and purpose matter. Internal workforce access policies remain separate from the external treatment-disclosure exception.
Apply it
A verified treating clinician requests medicines and allergies to resolve an urgent therapy question. Communicate the treatment information securely instead of incorrectly withholding it under minimum necessary.
Common pitfall: Extending the exception to every employee's access confuses disclosures with workforce permissions. Treatment does not justify curiosity-based access or careless transmission.
59.Why should information-system access identify the individual user?
Individual accountability connects system activity with authorized responsibilities and helps investigate errors or inappropriate access. Shared credentials obscure who performed an action and can undermine role-based permissions. The outline includes confidentiality and pharmacy information systems, while HHS describes access according to workforce roles. Access arrangements should support necessary care while preserving meaningful review of how patient information and prescription records were accessed, entered, or changed.
Apply it
Staff share an account to save time. Establish individually attributable access and suitable permissions so prescription changes and profile access can be assessed against each person's responsibilities.
Common pitfall: A shared-account audit trail may show that an action occurred without identifying its user. Administrative convenience does not provide reliable individual accountability.
HHS: HIPAA Minimum Necessary Requirement · California Board of Pharmacy Detailed Content Outline — Effective June 1, 2022
60.How should a shortage substitution be implemented safely?
A shortage response preserves the treatment goal while addressing changes in product, concentration, dosage form, route, availability, and authorization. Identify affected orders, obtain the appropriate treatment decision, update information systems and labels, and communicate changes. A new concentration requires different volume directions even if the intended dose remains unchanged. The outline includes availability changes and policy development, connecting purchasing responses with prescription evaluation, counseling, and administration safety.
Apply it
A liquid concentration becomes unavailable. Confirm an authorized alternative, recalculate volumes, update labels and relevant system entries, and have patients demonstrate the new measured dose.
Common pitfall: A purchasing substitution can silently change dosing if directions and devices are not updated. Availability alone does not establish interchangeability or authority.
California Board of Pharmacy Detailed Content Outline — Effective June 1, 2022 · Community Pharmacy/Hospital Outpatient Pharmacy Self-Assessment — Approved January 27, 2026
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Use the complete official outline as the scope map, then identify tasks requiring study beyond this selective guide.
- Identify decisive patient facts: actual exposure, reaction details, current renal function, administration limitations, and interacting medicines.
- Evaluate prescription completeness, authenticity, legality, clinical appropriateness, product selection, and final verification separately.
- Distinguish metformin initiation from continuation, release formulations, OTC eligibility from referral, and reporting from internal quality assurance.
- Connect treatment selection with duration, monitoring, non-drug measures, and demonstrated patient understanding.
- Practise inventory investigations, vaccine excursions, recalls, confidentiality decisions, and shortage substitutions using concrete evidence and applicable deadlines.
- Distinguish enacted law, effective regulations, Board guidance, and pending proposals when studying changing practice requirements.
- Patient Information and Prescription Evaluation task crosswalk: selected instruction addresses 1.A.1–6 through histories, records, prescription assessment, and renal findings; 1.A.9 through language needs and understanding; and 1.B.1–9 through product selection, preparation records, refill limits, labeling, final checks, automation, Shingrix, administration authority, and compounding distinctions. Physical assessment technique, including blood-pressure measurement and systematic observation of signs and symptoms (1.A.7), and health-screening procedures, including glucose checks and diagnostic testing (1.A.8), are not taught. The dispensing examples do not provide complete controlled-substance, immunization, administration, or compounding instruction.
- Clinical Practice task crosswalk: selected instruction addresses treatment decisions and monitoring in 2.A.1–6, 2.A.8–14, and patient education in 2.B.1–3, 2.B.5–7, and 2.B.9–10. Authority and selected examples introduce 2.A.7 and 2.A.15, but complete collaborative-management and pharmacist-provider therapy pathways are not taught. Herbal, complementary, and alternative-product counseling (2.B.4), and education of health professionals through precepting or structured drug-information responses (2.B.8), are not taught. Additional study is also needed for comprehensive immunization assessment, disease-specific regimens, device instruction, and monitoring beyond the selected medicines.
- Pharmacy Operations task crosswalk: selected instruction addresses inventory, records, recalls, shortages, and emergency storage in 3.A.1 and 3.A.3–8; quality measures and error analysis in 3.B.3–5; and compliance, selected supervision conditions, confidentiality, procedures, and systems in 3.C.1–5. Ordering procedures, including controlled-substance procurement (3.A.2), comprehensive personnel-competency assessment (3.B.1), administration-system evaluation using infusion-pump reports or barcode administration (3.B.2), and a complete adverse-reaction reporting system (3.B.6) are not taught. Supplier traceability, disposal, diversion controls, emergency response, staffing management, and information-system implementation receive selected examples rather than complete procedural instruction.
A practical preparation plan
1. Build a task-based study map
Read every task in the official outline. Mark whether you can explain it, apply it to a case, or need further study. Allocate review across the three domains and adjust for demonstrated weaknesses.
2. Practise prescription decisions
Identify intended treatment, current patient information, legal authority, selected product, label, and verification target. State the exact discrepancy and the information or correction needed to resolve it.
3. Link clinical criteria with actions
Compare renal thresholds, interactions, adverse-effect warning signs, OTC eligibility, treatment duration, and monitoring. Explain how changing one patient fact changes the recommended action.
4. Rehearse communication
Explain a regimen plainly, ask for teach-back, and correct one misunderstanding at a time. Use return demonstrations for measured doses and devices.
5. Work operational scenarios
Walk through a controlled-substance loss, vaccine excursion, recall, medication error, privacy request, and shortage. Identify actions, documentation, timing, and criteria for resuming use.
6. Use the drills diagnostically
Answer each question before reading its explanation. Record the decisive cue and explain why each alternative fails. Revisit difficult decisions with a changed result, symptom, product identifier, or trigger.
7. Close gaps with spaced review
Use flashcards for spaced recall, revisit missed concepts with their authorities, and complete remaining outline tasks. Keep clinical eligibility, administration sequences, and operational deadlines distinct enough to apply accurately.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- Pharmacist Examination and Licensure Information
- California Board of Pharmacy Detailed Content Outline — Effective June 1, 2022
- CPJE Candidate Information Bulletin — Updated December 2024
- Community Pharmacy/Hospital Outpatient Pharmacy Self-Assessment — Approved January 27, 2026
- California State Board of Pharmacy Frequently Asked Questions
- Translations of Pill Directions
- California Medication Error Reporting Fact Sheet — Revised May 20, 2025
- DailyMed: Metformin Hydrochloride Tablets
- DailyMed: Nitroglycerin Sublingual Tablets
- DailyMed: Lisinopril Tablets
- DailyMed: Alendronate Sodium Tablets
- DailyMed: Warfarin Sodium Tablets
- FDA: Don't Overuse Acetaminophen
- AHRQ: Use the Teach-Back Method — Tool 5
- AHRQ MATCH Toolkit, Chapter 3: Designing the Medication Reconciliation Process
- DEA Pharmacist's Manual — 2022 Edition
- DEA Diversion Control Division: Theft or Loss Q&A
- CDC Vaccine Storage and Handling Toolkit — July 2026
- HHS: HIPAA Minimum Necessary Requirement
- FDA: Understanding Drug Recalls — What to Know and What to Do
- camer_fact_sheet.pdf
- Federal Register, Volume 88 Issue 119 (Thursday, June 22, 2023)
- Frequently Asked Questions - California State Board of Pharmacy
- 26_jan_bd_mat_xii.pdf
- Pending Regulations - California State Board of Pharmacy
- download
- lawbook.pdf
- new_laws.pdf
- 1735_38_oa.pdf
- Controlled Substance Utilization Review and Evaluation System | State of California - Department of Justice - Office of the Attorney General
- ab-82-update-on-reporting-of-testosterone-and-mifepristone.pdf
- DailyMed - METFORMIN HYDROCHLORIDE tablet, film coated METFORMIN HYDROCHLORIDE tablet, extended release
- DailyMed - OMEPRAZOLE capsule, delayed release
- Frequently Asked Questions - California State Board of Pharmacy
- lawbook.pdf
- DailyMed - NICOTINE TRANSDERMAL SYSTEM patch
- Eating, Diet, & Nutrition for GER & GERD - NIDDK
- 1711_isor.pdf
- new_laws.pdf
- 1735_38_oa.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.